Sigachi Industries Ltd Upgraded to Sell on Technical and Valuation Improvements

Technical Trends Show Signs of Stabilisation

The primary driver behind the upgrade is a notable improvement in the technical grade, which shifted from bearish to mildly bearish. Weekly MACD readings have turned mildly bullish, suggesting some short-term momentum building, although monthly MACD remains bearish, indicating longer-term caution. The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, reflecting a neutral momentum stance.

Bollinger Bands remain mildly bearish on both weekly and monthly timeframes, while daily moving averages continue to signal mild bearishness. The KST indicator, a momentum oscillator, remains bearish on both weekly and monthly scales, underscoring persistent downward pressure. However, the Dow Theory presents a mixed picture with a mildly bullish weekly trend contrasting a bearish monthly trend. On-balance volume (OBV) shows no discernible trend, indicating a lack of strong buying or selling pressure.

These technical nuances suggest that while the stock is not out of the woods, the downward momentum is easing, justifying the upgrade from Strong Sell to Sell. The stock price closed at ₹20.84 on 8 April 2026, up 8.65% on the day, with a 52-week low of ₹18.26 and a high of ₹59.50, highlighting significant volatility over the past year.

Valuation Metrics Improve to Attractive from Very Attractive

Alongside technical improvements, Sigachi Industries’ valuation grade was upgraded from very attractive to attractive. The company currently trades at a price-to-earnings (PE) ratio of 19.48, which is lower than many of its pharmaceutical peers such as Bliss GVS Pharma (PE 24.18) and Kwality Pharma (PE 26.98). The price-to-book value stands at 1.57, while enterprise value to EBITDA is 13.05, indicating a reasonable valuation relative to earnings before interest, tax, depreciation and amortisation.

Return on capital employed (ROCE) is at 13.15%, and return on equity (ROE) at 12.07%, both reflecting moderate efficiency in generating returns. Dividend yield remains modest at 0.48%. The PEG ratio is reported as zero, which may indicate either no earnings growth or data limitations, but the overall valuation remains more attractive than many competitors, including Shukra Pharma and NGL Fine Chem, which are classified as very expensive.

This valuation upgrade suggests that the stock is trading at a discount compared to its historical averages and peer group, providing a more compelling entry point for investors willing to accept the associated risks.

Financial Trend Remains Weak Despite Some Debt Servicing Strength

Despite the upgrade in technical and valuation parameters, Sigachi Industries’ financial trend remains a significant concern. The company reported very negative financial performance in Q3 FY25-26, with net sales declining by 7.41% and operating profit growth stagnating at an annualised rate of just 0.55% over the past five years. The latest quarter’s profit after tax (PAT) fell sharply by 93.9% to ₹0.93 crore, marking the second consecutive quarter of negative results.

Operating profit to interest coverage ratio is at a low 1.82 times, signalling limited buffer to meet interest obligations. The half-year ROCE is at a low 13.13%, consistent with the company’s modest returns. Furthermore, promoter share pledging has increased to 40.32%, up 0.77% from the previous quarter, which could exert additional downward pressure on the stock in volatile markets.

Long-term returns have been disappointing, with the stock delivering -44.74% over the past year and -12.79% over three years, underperforming the Sensex and BSE500 indices significantly. Year-to-date returns are also negative at -33.1%, compared to the Sensex’s -8.99%.

On a positive note, the company maintains a low debt-to-EBITDA ratio of 1.56 times, indicating a manageable debt load relative to earnings, which may provide some financial stability amid operational challenges.

Quality Assessment and Market Capitalisation Context

Sigachi Industries is classified as a micro-cap company within the Pharmaceuticals & Biotechnology sector, which inherently carries higher volatility and risk. The company’s Mojo Grade has improved from Strong Sell to Sell, reflecting a cautious optimism but still signalling significant concerns regarding quality and financial health.

The overall Mojo Score of 31.0 remains low, underscoring the need for investors to exercise prudence. The company’s recent price action, with an 8.65% gain on the day of the upgrade, suggests some renewed investor interest, but the stock remains far below its 52-week high of ₹59.50.

Comparatively, the company’s returns lag behind the broader market indices, with the Sensex delivering 4.49% over the past year and 29.63% over three years, highlighting the stock’s underperformance in a generally positive market environment.

Conclusion: A Cautious Upgrade Amid Lingering Challenges

The upgrade of Sigachi Industries Ltd’s investment rating from Strong Sell to Sell is primarily driven by technical improvements and a more attractive valuation relative to peers. However, the company’s weak financial performance, declining sales, and high promoter share pledging continue to weigh heavily on its outlook.

Investors should weigh the modest technical recovery and valuation appeal against the persistent operational and financial headwinds. While the stock may offer some value at current levels, the risks remain elevated, and a cautious approach is warranted until clearer signs of sustained financial turnaround emerge.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →